Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
200 shown of 6,031 total abstracts
  1. Abstract 18832026-06-02 · 18:00 CT · Hall B1
    KEYNOTE-700: Keytruda (pembrolizumab) adjuvant in TNBC
    S. Tolaney, M. Krop, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 55022026-06-05 · 21:30 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in prostate
    S. Peters, J. Brahmer, T. Mok, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  3. Abstract 16082026-06-03 · 14:45 CT · Hall B1
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    J. Brahmer, H. Borghaei, F. Andre, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 17962026-06-05 · 18:00 CT · S100A
    IMpower-107: Tecentriq (atezolizumab) neoadjuvant in TNBC
    L. Paz-Ares, S. Modi, R. Herbst · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 99782026-06-03 · 15:45 CT · Hall B1
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-996
    P. Schmid, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 43312026-06-03 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-200 study)
    F. Andre, E. Winer, H. Borghaei, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 17632026-06-02 · 14:00 CT · S100A
    Quality of life outcomes with Trodelvy in patients with TNBC
    E. Winer, T. Mok, C. Robert, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 66452026-06-05 · 13:30 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in RCC
    J. Cortes, M. Krop, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 90542026-06-01 · 16:15 CT · S406
    Quality of life outcomes with Opdivo in patients with NSCLC
    S. Peters, H. Borghaei, L. Paz-Ares · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 16242026-06-01 · 21:15 CT · S100A
    MONALEESA-783: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    C. Saura, C. Robert, P. Schmid, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 95792026-06-03 · 19:00 CT · S100A
    Quality of life outcomes with Imfinzi in patients with NSCLC
    M. Krop, F. Andre, S. Antonia, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract 15312026-06-01 · 15:45 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-518 study)
    M. Krop, S. Antonia, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 10252026-06-04 · 18:00 CT · E450
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-543
    S. Peters, G. Curigliano, T. Mok, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 10832026-06-05 · 15:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-438 study)
    S. Tolaney, G. Curigliano, A. Spira, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 16962026-06-02 · 20:15 CT · Hall B1
    MONARCH-8: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    M.C. Garassino, H. Rugo, J. Cortes · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 99012026-06-05 · 16:45 CT · E450
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Peters, L. Paz-Ares, M. Reck, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract 41982026-06-03 · 13:15 CT · S100A
    Long-term follow-up of Imfinzi 2L for biliary tract: PACIFIC-178
    E. Winer, T. Mok, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Poster SessionGastrointestinal Cancer📄🖼️
  18. Abstract 14652026-06-02 · 14:00 CT · Arie Crown Theater
    MONALEESA-873: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    C. Robert, H. Borghaei, S. Peters · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 40952026-06-04 · 13:00 CT · Arie Crown Theater
    EV-860: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    N. Rizvi, M. Krop, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  20. Abstract 94402026-06-03 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-508 study)
    A. Spira, L. Paz-Ares · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 92922026-06-05 · 19:30 CT · E450
    Long-term follow-up of Keytruda 1L for NSCLC: KEYNOTE-36
    R. Herbst, C. Saura, T. Mok · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 97852026-06-04 · 15:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-841
    A. Spira, S. Antonia, F. Andre, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 13432026-06-04 · 19:15 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-906
    S. Peters, J. Cortes, J. Brahmer, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 43412026-06-05 · 19:45 CT · Hall B1
    DESTINY-Breast-108: Enhertu (trastuzumab deruxtecan) maintenance in gastric
    S. Modi, H. Borghaei, P. Schmid · Massachusetts General Hospital
    Poster SessionGastrointestinal Cancer📄🖼️
  25. Abstract 92932026-06-02 · 20:45 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    M. Krop, N. Rizvi, P. Schmid · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 92362026-06-04 · 18:30 CT · S100A
    Quality of life outcomes with Keytruda in patients with NSCLC
    S. Peters, M. Reck, M. Krop, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 45182026-06-04 · 15:45 CT · S100A
    EV-588: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    T. Mok, C. Saura · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  28. Abstract 15672026-06-03 · 14:00 CT · S100A
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-677
    C. Robert, M. Krop, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 11532026-06-02 · 21:00 CT · S100A
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    G. Curigliano, S. Antonia, E. Winer, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 57262026-06-01 · 19:30 CT · Hall B1
    Long-term follow-up of Lynparza 2L for prostate: OlympiA-41
    H. Borghaei, T. Mok, M.C. Garassino, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  31. Abstract 98502026-06-04 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-367 study)
    L. Paz-Ares, T. Mok · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract 17002026-06-05 · 14:15 CT · Hall B1
    IMpower-430: Tecentriq (atezolizumab) 1L in TNBC
    J. Cortes, R. Herbst, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 99402026-06-02 · 13:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-880
    H. Rugo, J. Brahmer, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  34. Abstract 90922026-06-04 · 15:45 CT · S100A
    KEYNOTE-832: Keytruda (pembrolizumab) maintenance in NSCLC
    S. Antonia, C. Robert, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  35. Abstract 11082026-06-02 · 14:00 CT · Hall B1
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    T. Mok, M. Reck · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 11822026-06-01 · 18:15 CT · Arie Crown Theater
    MONALEESA-828: Kisqali (ribociclib) maintenance in HR+ breast cancer
    L. Paz-Ares, A. Spira, H. Borghaei, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 90922026-06-03 · 15:00 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    N. Rizvi, H. Borghaei · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 49202026-06-01 · 15:30 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    M. Krop, J. Cortes · Dana-Farber Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  39. Abstract 16442026-06-04 · 15:15 CT · S406
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    J. Cortes, M.C. Garassino · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 10862026-06-01 · 15:45 CT · S406
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    M. Reck, S. Tolaney · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 101252026-06-01 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-332 study)
    M. Reck, C. Robert · University of Chicago
    Poster SessionMelanoma📄🖼️
  42. Abstract 41902026-06-03 · 18:00 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in HCC
    E. Winer, H. Borghaei, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  43. Abstract 90072026-06-04 · 14:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-876
    C. Saura, S. Antonia · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 44612026-06-03 · 20:15 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-498
    N. Rizvi, C. Saura, S. Modi · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  45. Abstract 93442026-06-02 · 20:45 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-805 study)
    G. Curigliano, C. Saura, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  46. Abstract 18812026-06-04 · 13:30 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    S. Tolaney, G. Curigliano, N. Rizvi, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 19122026-06-01 · 19:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-413 study)
    H. Rugo, J. Cortes · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 16442026-06-01 · 20:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-343
    M.C. Garassino, S. Antonia, A. Spira, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 49502026-06-03 · 15:00 CT · S406
    Long-term follow-up of Trodelvy neoadjuvant for urothelial carcinoma: ASCENT-621
    A. Spira, L. Paz-Ares, H. Borghaei, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  50. Abstract 13302026-06-03 · 18:00 CT · E450
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-134
    P. Schmid, S. Tolaney, S. Antonia · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 46532026-06-05 · 21:30 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-764 study)
    S. Antonia, J. Brahmer, G. Curigliano, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  52. Abstract 45852026-06-03 · 14:45 CT · S100A
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    P. Schmid, S. Tolaney, N. Rizvi · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  53. Abstract 17072026-06-04 · 15:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-200
    P. Schmid, S. Antonia, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 55012026-06-03 · 19:00 CT · Arie Crown Theater
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    S. Tolaney, H. Borghaei, T. Mok · Royal Marsden Hospital
    Poster SessionGynecologic Cancer📄🖼️
  55. Abstract 14062026-06-03 · 18:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-319 study)
    T. Mok, P. Schmid, M. Reck, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 44672026-06-03 · 20:15 CT · Hall B1
    Long-term follow-up of Tecentriq 3L+ for HCC: IMpower-852
    L. Paz-Ares, S. Tolaney, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Poster SessionGastrointestinal Cancer📄🖼️
  57. Abstract 14672026-06-02 · 14:00 CT · Arie Crown Theater
    PALOMA-387: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    S. Peters, P. Schmid, J. Brahmer · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 96952026-06-05 · 15:00 CT · S100A
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-349
    R. Herbst, M. Reck, A. Spira, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  59. Abstract 96642026-06-04 · 21:00 CT · Arie Crown Theater
    FLAURA-445: Tagrisso (osimertinib) 2L in NSCLC
    P. Schmid, J. Cortes, C. Robert, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  60. Abstract 43522026-06-04 · 15:15 CT · S406
    DESTINY-Breast-132: Enhertu (trastuzumab deruxtecan) 1L in gastric
    H. Borghaei, P. Schmid · Cleveland Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  61. Abstract 96542026-06-01 · 21:15 CT · S406
    Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-482
    S. Peters, J. Brahmer, G. Curigliano · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  62. Abstract 95012026-06-02 · 15:45 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    H. Borghaei, J. Brahmer, H. Rugo · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  63. Abstract 99682026-06-03 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-617 study)
    A. Spira, M. Krop · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 17852026-06-05 · 15:45 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-678
    J. Brahmer, M. Reck, H. Rugo · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 94012026-06-03 · 15:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-376
    P. Schmid, H. Rugo · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  66. Abstract 104922026-06-02 · 20:00 CT · S406
    CheckMate-626: Opdivo (nivolumab) maintenance in metastatic melanoma
    J. Cortes, J. Brahmer, C. Saura, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  67. Abstract 96962026-06-05 · 14:00 CT · S100A
    Long-term follow-up of Tecentriq maintenance for NSCLC: IMpower-284
    S. Peters, E. Winer · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 94882026-06-04 · 14:45 CT · Arie Crown Theater
    KEYNOTE-659: Keytruda (pembrolizumab) 2L in SCLC
    J. Brahmer, H. Rugo · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  69. Abstract 90612026-06-04 · 19:45 CT · Hall B1
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-782
    J. Cortes, S. Modi, E. Winer, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  70. Abstract 99572026-06-01 · 19:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-273 study)
    M. Reck, T. Mok, A. Spira · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  71. Abstract 100282026-06-04 · 15:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-437
    L. Paz-Ares, E. Winer, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  72. Abstract 96662026-06-02 · 13:00 CT · S100A
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-852
    H. Rugo, C. Saura, J. Brahmer · Institut Gustave Roussy
    Poster SessionLung Cancer—Small Cell📄🖼️
  73. Abstract 92162026-06-02 · 16:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-380
    H. Rugo, G. Curigliano, S. Tolaney · Massachusetts General Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  74. Abstract 68672026-06-03 · 15:45 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in RCC
    M.C. Garassino, S. Tolaney, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  75. Abstract 17152026-06-05 · 14:30 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    M.C. Garassino, F. Andre · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 13932026-06-01 · 13:30 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    T. Mok, N. Rizvi · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 45152026-06-05 · 16:45 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with HCC
    P. Schmid, M.C. Garassino, S. Peters · MD Anderson Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  78. Abstract 18692026-06-01 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-174 study)
    E. Winer, C. Saura · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 12802026-06-03 · 21:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-39
    H. Rugo, P. Schmid · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 19942026-06-02 · 16:30 CT · E450
    ASCENT-663: Trodelvy (sacituzumab govitecan) 1L in TNBC
    S. Modi, H. Rugo, H. Borghaei · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 96082026-06-02 · 13:30 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-267
    R. Herbst, C. Robert, G. Curigliano, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  82. Abstract 44852026-06-01 · 18:30 CT · S100A
    Long-term follow-up of Trodelvy 2L for urothelial carcinoma: ASCENT-797
    C. Saura, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  83. Abstract 90182026-06-03 · 16:30 CT · S406
    PACIFIC-277: Imfinzi (durvalumab) neoadjuvant in NSCLC
    H. Borghaei, J. Cortes · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  84. Abstract 40062026-06-03 · 21:00 CT · S406
    IMpower-83: Tecentriq (atezolizumab) 2L in HCC
    H. Borghaei, C. Saura, M.C. Garassino · Mayo Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  85. Abstract 90762026-06-01 · 15:15 CT · Arie Crown Theater
    IMpower-771: Tecentriq (atezolizumab) adjuvant in NSCLC
    A. Spira, M.C. Garassino · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 11272026-06-04 · 21:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-872
    S. Peters, M. Reck · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 47432026-06-04 · 18:00 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    J. Cortes, J. Brahmer, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  88. Abstract 19892026-06-01 · 13:45 CT · S406
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-886
    L. Paz-Ares, F. Andre · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 42322026-06-03 · 19:15 CT · S406
    Long-term follow-up of Trodelvy 2L for urothelial carcinoma: ASCENT-716
    F. Andre, M. Krop, T. Mok · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  90. Abstract 45682026-06-03 · 20:30 CT · Hall B1
    IMpower-928: Tecentriq (atezolizumab) neoadjuvant in HCC
    J. Brahmer, N. Rizvi, S. Tolaney, et al. · Royal Marsden Hospital
    Poster SessionGastrointestinal Cancer📄🖼️
  91. Abstract 101682026-06-05 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-470
    P. Schmid, C. Robert, J. Cortes, et al. · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  92. Abstract 17922026-06-01 · 19:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-204
    L. Paz-Ares, M.C. Garassino, S. Tolaney, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 12242026-06-05 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-618 study)
    T. Mok, M. Reck, S. Modi · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 45612026-06-03 · 15:30 CT · E450
    Long-term follow-up of Trodelvy neoadjuvant for urothelial carcinoma: ASCENT-252
    J. Brahmer, S. Antonia, J. Cortes · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  95. Abstract 97292026-06-02 · 15:15 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    M.C. Garassino, L. Paz-Ares, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  96. Abstract 19772026-06-02 · 21:00 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-395
    C. Saura, E. Winer, H. Borghaei, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 57012026-06-03 · 19:15 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with ovarian
    L. Paz-Ares, M.C. Garassino, J. Brahmer, et al. · Stanford Cancer Institute
    Poster SessionGynecologic Cancer📄🖼️
  98. Abstract 92582026-06-01 · 15:00 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-833 study)
    H. Rugo, R. Herbst, A. Spira · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  99. Abstract 10192026-06-02 · 19:30 CT · Arie Crown Theater
    MONALEESA-526: Kisqali (ribociclib) 2L in HR+ breast cancer
    F. Andre, C. Robert, M. Reck, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 14692026-06-04 · 18:45 CT · S406
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-569
    S. Modi, L. Paz-Ares, C. Robert · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 15072026-06-03 · 15:45 CT · Arie Crown Theater
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    S. Tolaney, M. Reck, J. Cortes, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 14902026-06-04 · 16:30 CT · S406
    MONARCH-358: Verzenio (abemaciclib) 1L in HR+ breast cancer
    G. Curigliano, P. Schmid, F. Andre · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 47202026-06-03 · 16:00 CT · Hall B1
    EV-176: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    M.C. Garassino, A. Spira, M. Krop, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  104. Abstract 64542026-06-02 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza adjuvant for ovarian: OlympiA-810
    M. Krop, H. Rugo, S. Antonia · Stanford Cancer Institute
    Poster SessionGynecologic Cancer📄🖼️
  105. Abstract 40462026-06-02 · 21:15 CT · S406
    Long-term follow-up of Enhertu maintenance for gastric: DESTINY-Breast-328
    T. Mok, C. Robert, S. Tolaney, et al. · MD Anderson Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  106. Abstract 11032026-06-01 · 16:15 CT · Arie Crown Theater
    MONARCH-619: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    S. Antonia, F. Andre, M. Krop · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 62732026-06-04 · 18:00 CT · S100A
    CheckMate-897: Opdivo (nivolumab) neoadjuvant in RCC
    F. Andre, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  108. Abstract 41792026-06-04 · 15:45 CT · Hall B1
    IMpower-399: Tecentriq (atezolizumab) 2L in HCC
    S. Modi, T. Mok, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGastrointestinal Cancer📄🖼️
  109. Abstract 96912026-06-05 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-755 study)
    H. Borghaei, A. Spira, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 41082026-06-02 · 15:15 CT · S100A
    PACIFIC-897: Imfinzi (durvalumab) maintenance in biliary tract
    M. Krop, F. Andre · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  111. Abstract 91142026-06-02 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-614
    M. Krop, S. Antonia, C. Robert, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  112. Abstract 61892026-06-04 · 19:30 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with RCC
    S. Tolaney, N. Rizvi, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  113. Abstract 98882026-06-05 · 15:30 CT · S406
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    R. Herbst, C. Saura, J. Brahmer · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  114. Abstract 91352026-06-02 · 13:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-620 study)
    E. Winer, S. Modi, P. Schmid, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  115. Abstract 44552026-06-02 · 15:15 CT · Hall B1
    EV-719: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    J. Cortes, L. Paz-Ares, C. Saura, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  116. Abstract 17482026-06-04 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-942
    S. Tolaney, G. Curigliano · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 93652026-06-02 · 21:30 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    N. Rizvi, G. Curigliano, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  118. Abstract 52252026-06-03 · 15:15 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-314
    S. Tolaney, A. Spira · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  119. Abstract 13452026-06-05 · 21:00 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-53
    S. Antonia, T. Mok, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 56112026-06-01 · 16:15 CT · Hall B1
    Long-term follow-up of Lynparza maintenance for ovarian: OlympiA-247
    L. Paz-Ares, F. Andre, C. Saura, et al. · Karolinska Institute
    Poster SessionGynecologic Cancer📄🖼️
  121. Abstract 92612026-06-05 · 18:45 CT · E450
    Long-term follow-up of Opdivo 1L for NSCLC: CheckMate-538
    S. Modi, H. Borghaei · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  122. Abstract 47362026-06-01 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-3 study)
    S. Tolaney, L. Paz-Ares, J. Cortes · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  123. Abstract 48502026-06-03 · 21:30 CT · S406
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    J. Cortes, J. Brahmer, A. Spira, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  124. Abstract 45862026-06-02 · 15:00 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-389
    M. Krop, A. Spira, J. Cortes · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  125. Abstract 12782026-06-01 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-93 study)
    P. Schmid, M. Krop · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 93992026-06-03 · 21:30 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-633
    H. Borghaei, M. Reck · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  127. Abstract 13692026-06-03 · 18:00 CT · S406
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-684
    S. Tolaney, M. Krop, P. Schmid, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 98312026-06-02 · 21:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-388
    M. Krop, L. Paz-Ares, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  129. Abstract 16382026-06-02 · 18:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-122 study)
    C. Robert, S. Antonia, S. Tolaney, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 44492026-06-01 · 18:30 CT · S100A
    Quality of life outcomes with Imfinzi in patients with biliary tract
    H. Rugo, M.C. Garassino · Cleveland Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  131. Abstract 16892026-06-04 · 15:15 CT · S406
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-435
    L. Paz-Ares, S. Antonia, P. Schmid · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 16582026-06-03 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-346 study)
    A. Spira, S. Peters, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 49732026-06-02 · 19:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-428
    C. Robert, E. Winer, S. Antonia, et al. · Karolinska Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  134. Abstract 43172026-06-04 · 20:00 CT · E450
    ASCENT-824: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    S. Modi, S. Antonia, H. Rugo, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  135. Abstract 17232026-06-03 · 20:45 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-371
    E. Winer, F. Andre · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 99272026-06-02 · 16:00 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    C. Robert, E. Winer · MD Anderson Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  137. Abstract 16482026-06-02 · 13:30 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    J. Brahmer, M. Krop, C. Robert · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 17332026-06-02 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-803
    M. Reck, A. Spira, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 46922026-06-03 · 15:00 CT · E450
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-923 study)
    A. Spira, M.C. Garassino, F. Andre, et al. · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  140. Abstract 41672026-06-02 · 18:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-770
    P. Schmid, S. Peters, G. Curigliano, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  141. Abstract 57432026-06-02 · 16:00 CT · S406
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-177
    G. Curigliano, C. Saura, M. Krop · Stanford Cancer Institute
    Poster SessionGynecologic Cancer📄🖼️
  142. Abstract 95482026-06-02 · 18:45 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-306
    P. Schmid, A. Spira · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  143. Abstract 45162026-06-03 · 19:15 CT · E450
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-552
    T. Mok, M. Krop, R. Herbst · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  144. Abstract 92592026-06-03 · 19:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-687
    R. Herbst, S. Modi · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  145. Abstract 42192026-06-04 · 15:00 CT · E450
    Long-term follow-up of Enhertu 3L+ for gastric: DESTINY-Breast-409
    F. Andre, S. Tolaney · Royal Marsden Hospital
    Poster SessionGastrointestinal Cancer📄🖼️
  146. Abstract 98722026-06-03 · 21:45 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    S. Peters, L. Paz-Ares, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  147. Abstract 14942026-06-04 · 16:15 CT · S406
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-82
    A. Spira, E. Winer, S. Modi · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 16882026-06-02 · 20:45 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-518
    S. Peters, S. Tolaney · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 48012026-06-05 · 14:15 CT · Arie Crown Theater
    PACIFIC-348: Imfinzi (durvalumab) 3L+ in biliary tract
    M.C. Garassino, M. Reck, S. Peters · Chinese University of Hong Kong
    Poster SessionGastrointestinal Cancer📄🖼️
  150. Abstract 14722026-06-01 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-737
    H. Borghaei, F. Andre, C. Saura · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 99152026-06-02 · 21:15 CT · S100A
    FLAURA-670: Tagrisso (osimertinib) neoadjuvant in NSCLC
    F. Andre, H. Borghaei, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  152. Abstract 44092026-06-05 · 21:30 CT · Hall B1
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-353
    C. Saura, J. Brahmer, S. Modi, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  153. Abstract 98862026-06-05 · 15:00 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    S. Modi, S. Antonia, N. Rizvi · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  154. Abstract 96052026-06-04 · 13:30 CT · Hall B1
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-891
    P. Schmid, F. Andre, S. Tolaney, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  155. Abstract 90652026-06-02 · 19:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-578
    M.C. Garassino, M. Reck · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  156. Abstract 48002026-06-01 · 13:00 CT · E450
    Long-term follow-up of Tecentriq maintenance for HCC: IMpower-56
    T. Mok, S. Peters, S. Modi · Cleveland Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  157. Abstract 16962026-06-02 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-46 study)
    H. Rugo, E. Winer, P. Schmid, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 49072026-06-02 · 15:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-426
    J. Brahmer, M.C. Garassino, F. Andre, et al. · Chinese University of Hong Kong
    Poster SessionGastrointestinal Cancer📄🖼️
  159. Abstract 15552026-06-05 · 13:30 CT · E450
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-905
    H. Rugo, G. Curigliano · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 48352026-06-01 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-281 study)
    N. Rizvi, P. Schmid, M. Reck, et al. · Chinese University of Hong Kong
    Poster SessionGastrointestinal Cancer📄🖼️
  161. Abstract 43942026-06-03 · 15:45 CT · E450
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-698
    E. Winer, G. Curigliano, J. Cortes · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  162. Abstract 49912026-06-05 · 21:15 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    H. Rugo, P. Schmid · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  163. Abstract 99162026-06-02 · 20:45 CT · Arie Crown Theater
    KEYNOTE-968: Keytruda (pembrolizumab) 3L+ in SCLC
    F. Andre, S. Antonia, S. Modi · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  164. Abstract 47272026-06-02 · 20:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in HCC (the CheckMate-346 study)
    F. Andre, L. Paz-Ares, M. Krop, et al. · Cleveland Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  165. Abstract 96562026-06-04 · 19:00 CT · E450
    CheckMate-476: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    A. Spira, S. Modi · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  166. Abstract 18292026-06-03 · 14:00 CT · Hall B1
    MONARCH-188: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    J. Brahmer, P. Schmid, H. Borghaei · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 49652026-06-05 · 18:45 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-486
    T. Mok, G. Curigliano, M. Reck, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  168. Abstract 17232026-06-02 · 20:00 CT · S406
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    F. Andre, S. Antonia · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 67452026-06-02 · 14:45 CT · Arie Crown Theater
    KEYNOTE-927: Keytruda (pembrolizumab) neoadjuvant in RCC
    C. Saura, E. Winer, S. Modi, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  170. Abstract 49902026-06-03 · 15:30 CT · Hall B1
    ASCENT-462: Trodelvy (sacituzumab govitecan) adjuvant in urothelial carcinoma
    E. Winer, M.C. Garassino · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  171. Abstract 48522026-06-01 · 13:00 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-790
    F. Andre, M.C. Garassino, C. Robert, et al. · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  172. Abstract 15712026-06-02 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-455
    A. Spira, T. Mok, G. Curigliano · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 18792026-06-02 · 14:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-559 study)
    S. Modi, F. Andre, T. Mok · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 90712026-06-02 · 19:00 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    C. Robert, N. Rizvi, H. Borghaei · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  175. Abstract 16612026-06-03 · 21:30 CT · E450
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-299
    S. Modi, E. Winer, C. Saura, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 12692026-06-04 · 18:15 CT · Hall B1
    MONARCH-273: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    P. Schmid, F. Andre, H. Rugo, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 92312026-06-04 · 20:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-94 study)
    T. Mok, H. Borghaei, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  178. Abstract 64852026-06-04 · 13:45 CT · S406
    Long-term follow-up of Lynparza adjuvant for ovarian: OlympiA-615
    S. Modi, M.C. Garassino, M. Krop, et al. · Karolinska Institute
    Poster SessionGynecologic Cancer📄🖼️
  179. Abstract 16132026-06-01 · 13:45 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-325
    S. Modi, J. Cortes, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 42542026-06-02 · 18:30 CT · E450
    ASCENT-458: Trodelvy (sacituzumab govitecan) adjuvant in urothelial carcinoma
    S. Tolaney, H. Borghaei, S. Peters, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  181. Abstract 99782026-06-02 · 21:00 CT · S100A
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-536
    C. Robert, R. Herbst, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  182. Abstract 19322026-06-02 · 13:45 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-48
    M. Krop, S. Antonia, N. Rizvi, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 92722026-06-05 · 16:00 CT · Hall B1
    PACIFIC-278: Imfinzi (durvalumab) 2L in NSCLC
    L. Paz-Ares, H. Rugo, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  184. Abstract 47232026-06-02 · 14:00 CT · S100A
    Quality of life outcomes with Opdivo in patients with HCC
    G. Curigliano, C. Robert, T. Mok · Chinese University of Hong Kong
    Poster SessionGastrointestinal Cancer📄🖼️
  185. Abstract 56062026-06-03 · 18:30 CT · Arie Crown Theater
    OlympiA-816: Lynparza (olaparib) adjuvant in prostate
    T. Mok, S. Modi · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  186. Abstract 18152026-06-04 · 16:00 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-521
    S. Peters, S. Antonia · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 96192026-06-05 · 20:15 CT · S406
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-928
    J. Cortes, C. Robert, S. Antonia · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  188. Abstract 14862026-06-03 · 15:45 CT · E450
    KEYNOTE-228: Keytruda (pembrolizumab) 1L in TNBC
    A. Spira, T. Mok, G. Curigliano · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 12922026-06-02 · 20:30 CT · Hall B1
    MONALEESA-910: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    P. Schmid, H. Rugo, R. Herbst, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 11542026-06-01 · 19:00 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-28
    G. Curigliano, L. Paz-Ares, S. Peters · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  191. Abstract 17822026-06-05 · 13:45 CT · S406
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-278
    N. Rizvi, P. Schmid, C. Saura · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  192. Abstract 11032026-06-01 · 16:15 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-370
    H. Rugo, A. Spira, M. Krop · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 40652026-06-01 · 15:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-525 study)
    M.C. Garassino, R. Herbst · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  194. Abstract 13752026-06-02 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-897 study)
    N. Rizvi, C. Saura, J. Brahmer, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  195. Abstract 13102026-06-02 · 14:15 CT · S100A
    PALOMA-399: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    M. Reck, H. Rugo, S. Peters, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  196. Abstract 90592026-06-01 · 13:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-302 study)
    R. Herbst, J. Cortes, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  197. Abstract 93672026-06-04 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-325 study)
    J. Brahmer, H. Borghaei · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  198. Abstract 104962026-06-05 · 16:15 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-458 study)
    S. Tolaney, A. Spira, N. Rizvi · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  199. Abstract 45462026-06-04 · 19:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in gastric
    J. Brahmer, S. Peters, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGastrointestinal Cancer📄🖼️
  200. Abstract 95192026-06-04 · 19:30 CT · Hall B1
    FLAURA-424: Tagrisso (osimertinib) adjuvant in NSCLC
    R. Herbst, N. Rizvi, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.